Caliway schedules November 11 results for Caliway Biopharmaceuticals C stock
Published on 10/26/2026 at 15:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSReporting date and clinical progress
- Caliway has a scheduled results date of November 11, 2026.
- First-half 2026 revenue was TWD 3.568 million, versus TWD 12.212 million a year earlier.
- Caliway Biopharmaceuticals C stock was TWD 73.80 on October 22, 2026, down 2.89 percent on Taiwan and 60.74 percent below its 52-week high.
- Market capitalization was TWD 118.2 billion on October 20, 2026.
Caliway Biopharmaceuticals has scheduled its next results for November 11, 2026, while first-half revenue was TWD 3.568 million. The date and earnings figures were listed by Investing.com. Caliway Biopharmaceuticals C stock was TWD 73.80 on October 22, 2026, down 2.89 percent from TWD 76.00.
Revenue remains small
The first-half result underlines the gap between Caliway's development ambitions and its current commercial base. Quartr reported first-half 2026 revenue of TWD 3.568 million, down from TWD 12.212 million in the comparable period. Net loss narrowed to TWD 330.270 million from TWD 424.378 million, while operating expenses rose to TWD 511.244 million from TWD 393.249 million.
CBL-514 moves into phase 3
The company's investment case still rests on CBL-514 and its clinical development. In a release dated October 2, 2026, Caliway Biopharmaceuticals said phase 3 recruitment had started. In phase 2, 69.60 percent of treated participants achieved at least 150 milliliters of subcutaneous fat reduction at the eight-week follow-up, compared with 0 percent for placebo.
Taiwan price reaches yearly low
The October 22 close matched the 52-week low of TWD 73.80 and stood 60.74 percent below the TWD 188.00 high, based on the historical price table from Investing.com. The same table listed a session range of TWD 73.80 to TWD 76.80 and volume of 2.74 million shares for that date.
Valuation and reporting date
Barrons listed Caliway on Taiwan with ticker 6919 and market capitalization of TWD 118.2 billion on October 20, 2026. The company operates in pharmaceuticals and focuses on medical aesthetics and small-molecule therapeutics. The November 11 reporting date gives investors the next scheduled checkpoint for revenue, losses and development spending.
Market context: Market report TAIEX.
More news and analyses on Caliway Biopharmaceuticals C stock
